Successful management of a high-risk pregnancy with polyhydramnios, IUGR and recurrent pregnancy loss in a chronic renal failure patient: a case report.

Pregnancy in patients with chronic renal failure occurs rarely but the incidence is increasing. The successful management of a 38-year-old woman suffering from chronic renal failure is discussed.

Hemophagocytic syndrome in kidney transplant recipients: report of four cases from a single center.

Background: The prognosis of hemophagocytic syndrome (HPS) in kidney transplant recipients is reported to be poor, however the optimal therapeutic approach is still unclear.

Patients And Methods: The clinical and follow-up data of the 4 patients with HPS (3 male, 1 female; age 39.7 +/- 11.

Kidney-pancreas transplantation: single-center experience at a university hospital in Turkey.

Introduction: One treatment option for patients with type 1 diabetes mellitus with end-stage nephropathy is combined pancreas-kidney transplantation, which can be performed either simultaneously (SPK) or following kidney transplantation (PAK).

Patients And Methods: Between February 2003 and November 2004, 14 patients, including 10 males and 4 females of overall mean age of 31.3 +/- 6.

Tacrolimus plus low-dose mycophenolate mofetil in renal transplant recipients: better 2-year graft and patient survival than with a higher mycophenolate mofetil dose.

Objectives: Mycophenolate mofetil (MMF) has become more widely prescribed in recent years, but its adverse effects on the gastrointestinal system and bone marrow restrict its use in certain settings. The aim of this study was to compare the demographic features and clinical data for 173 renal transplant recipients who received tacrolimus (TAC) plus 1 g/d MMF (group I, n = 112) versus TAC plus 2 g/d MMF (group II, n = 61 patients) over a 2-year period. Each patient received similar TAC doses.

Sirolimus as primary immunosuppression agent in kidney transplant recipients: Akdeniz University experience.

Objectives: Recently usage of sirolimus as the primary immunosuppressant is widening among kidney transplant recipients. We reviewed the clinical follow-up of patients transplanted at our center using sirolimus protocols.

Methods: Sirolimus including primary immunosuppressive treatment protocols were begun in February 2002.